オハイオにおける骨髄線維症の臨床試験
オハイオ内の拠点で、骨髄線維症に関する17件の研究が参加者を募集しています。
オハイオ内の都市
公式研究テキスト（英語）
A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF)
- The Ohio State University Comprehensive Cancer Center, Columbus
被験者募集中第3相
18歳以上 · 全性別 · 2026/10/01更新 · NCT07357727A Study to Compare Elritercept to Placebo in Adults With Myelofibrosis and Anemia Who Are Taking Ruxolitinib
- Cleveland Clinic, Cleveland
被験者募集中第3相
18歳以上 · 全性別 · 2026/10/01更新 · NCT07623161A Randomized Study of ASTX727 With or Without Iadademstat in Advanced Myeloproliferative Neoplasms (MPNs)
- Ohio State University Comprehensive Cancer Center, Columbus
被験者募集中第2相
18歳以上 · 全性別 · 2026/09/30更新 · NCT06661915Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia
- Cleveland Clinic, Cleveland
- The Ohio State University, Columbus
- Taylor Cancer Research Center, Maumee
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/23更新 · NCT05320198A Study of Oral Nuvisertib (TP-3654) in Patients With Myelofibrosis
- Ohio State University, Columbus
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/23更新 · NCT04176198A Phase 1 Study of LY5830966 in Participants With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF) Who Have Been Failed by a Type I JAK2 Inhibitor (JAK2i)
- University of Cincinnati, Cincinnati
- The Ohio State University Comprehensive Cancer Center, Columbus
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/17更新 · NCT06343805Pacritinib Effectiveness in Real-world Settings
- The Ohio State University, Columbus
被験者募集中観察研究
18歳以上 · 全性別 · 2026/09/14更新 · NCT07774455A Study of Ruxolitinib in Combination With Ulixertinib in People With Myelofibrosis
- Cleveland Clinic, Cleveland
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/07/28更新 · NCT06773195Study of INCA036978 in Participants With Myeloproliferative Neoplasms
- Cleveland Clinic, Cleveland
- Ohio State University, Columbus
被験者募集中第1相
18歳以上 · 全性別 · 2026/07/22更新 · NCT07441694Reparixin in Patients With Myelofibrosis Myeloproliferative Neoplasms Research Consortium (MPN-RC 120)
- The Cleveland Clinic Foundation, Cleveland
- The Ohio State University, Columbus
被験者募集中第2相
18歳以上 · 全性別 · 2026/05/06更新 · NCT05835466Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
- Cincinnati Children's Hospital Medical Center, Cincinnati
- University of Cincinnati, Cincinnati
- The Ohio State University, Columbus
被験者募集中第1相
13歳以上 · 全性別 · 2026/05/05更新 · NCT04771572A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms
- Cleveland Clinic, Cleveland
被験者募集中第1相
18歳以上 · 全性別 · 2026/04/17更新 · NCT06034002A Study to Evaluate Safety and Efficacy of Bomedemstat (MK-3543-017)
- The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive C ( Site 6007), Columbus
被験者募集中第3相
18歳以上 · 全性別 · 2026/04/02更新 · NCT06351631A Study of Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and Moderate Thrombocytopenia
- Cleveland Clinic, Cleveland
被験者募集中第2相
18歳以上 · 全性別 · 2026/02/12更新 · NCT05980806SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Cincinnati
- Massive Bio SYNERGY-AI site, Columbus
- Massive Bio SYNERGY-AI site, Mayfield Heights
被験者募集中観察研究
全年齢 · 全性別 · 2025/10/28更新 · NCT03452774Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib
- Gabrail Cancer Center, Canton
- University of Cincinnati Medical Center, Cincinnati
- Cleveland Clinic Cancer Center at Fairview Hospital, Cleveland
- 他3件
被験者募集中第3相
18歳以上 · 全性別 · 2025/09/25更新 · NCT06479135Study of TL-895 Combined With Ruxolitinib in JAKi Treatment-Naïve MF Subjects and Subjects With MF Who Have a Suboptimal Response to Ruxolitinib
- Gabrail Cancer Center, Canton
- University of Cincinnati (UC), Cincinnati
被験者募集中第1/2相
18歳以上 · 全性別 · 2023/02/21更新 · NCT05280509ClinicalTrials.govより、2026/10/02時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。